This disclosure relates to rifaximin—for use in the treatment of bacterial vaginal infections. The disclosure also relates to the use of rifaximin for treating infections characterized by the presence of bacteria that may be clindamycin and/or metronidazole resistant. The disclosure also relates to the use of rifaximin to treat patients with vaginal infections who have relapsed following prior treatment or who have bacteria resistant to antibiotics other than rifaximin.